Janux Therapeutics, Inc.
NASDAQ:JANXBiotechnology
Healthcare
$10.29 -1.74%
-$0.25 today
- Market cap
- $629.58M
- Beta
- 2.52
- P/E (TTM)
- -7.6
- EPS (TTM)
- -$1.83
52W Low $12.12High $35.34
Volume 0.65M
Average 1.02M
Balance Sheet
Inspect the capital base behind the business.
Assets
$1.01B
FY 2025 · Annual
-5.1% YoYLiabilities
$50.70M
FY 2025 · Annual
+30.9% YoYEquity
$956.82M
FY 2025 · Annual
-6.4% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 35.58M | 51.43M | 19.21M | 430.61M | 52.33M |
| Short-term Investments | 339.38M | 275.59M | 324.82M | 594.57M | 914.23M |
| Net Receivables | 0 | 700K | 2.16M | 5.38M | 6.43M |
| Inventory | 0 | (700K) | 0 | 0 | 0 |
| Other Current Assets | 0 | 5.42M | 0 | 0 | 0 |
| Total Current Assets | 377.02M | 332.44M | 349.24M | 1.03B | 975.89M |
| Property, Plant & Equipment (Net) | 1.6M | 29.37M | 27.84M | 24.15M | 22.25M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 816K | 0 | 0 | 816K |
| Tax Assets | 0 | 0 | 0 | 0 | 5.96M |
| Other Non-current Assets | 1.21M | 1.39M | 3.33M | 3.7M | 2.61M |
| Total Non-current Assets | 2.81M | 31.57M | 31.17M | 27.85M | 31.64M |
| Total Assets | 379.82M | 364.01M | 380.41M | 1.06B | 1.01B |
| Account Payables | 2.46M | 2.16M | 2.42M | 4.03M | 4.97M |
| Short-term Debt | 0 | 0 | 0 | 0 | 2.39M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 5.16M | 5.41M | 1.71M | 0 | 0 |
| Other Current Liabilities | 2.37M | 5.51M | 3.3M | 4.57M | 13.04M |
| Total Current Liabilities | 12.8M | 16.51M | 13.03M | 17.46M | 25M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 5.96M |
| Deferred Revenue (Non-current) | 700K | 2.22M | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 700K | 26.76M | 23.03M | 21.28M | 25.7M |
| Total Liabilities | 13.5M | 43.27M | 36.06M | 38.74M | 50.7M |
| Common Stock | 41K | 42K | 46K | 59K | 60K |
| Retained Earnings | (47.41M) | (110.47M) | (168.76M) | (237.76M) | (351.38M) |
| Accumulated OCI | (270K) | (1.54M) | 665K | 2.16M | 4.32M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 366.33M | 320.74M | 344.35M | 1.02B | 956.82M |
| Total Debt | 194K | 25.31M | 24.54M | 23.03M | 22.14M |
| Net Debt | (35.39M) | (26.12M) | 5.34M | (407.58M) | (30.2M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $51.8M |
| Short-term Investments | $904.6M |
| Receivables | $42.5M |
| Other Current | $3.2M |
| Total Current Assets | $1.0B |
| PP&E (Net) | $21.4M |
| Other Non-current | $4.8M |
| Total Non-current Assets | $26.2M |
| Total Assets | $1.0B |
Analysis
Selected assets total $1.0B for Latest. The largest visible component is Short-term Investments at $904.6M, about 88.0% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 14, 2026 | |
| SC 13G/A | SC 13G/A filing | Aug 13, 2026 |
How much cash does JANX have?
Janux Therapeutics, Inc. (JANX) reported $52.33M in cash and equivalents in fiscal 2025.
How much debt does JANX carry?
Janux Therapeutics, Inc. (JANX) reported $22.14M of total debt, with net debt of -$30.20M.
Continue the stock analysis
Jump to another research area for this company.